Stay updated on Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial

Sign up to get notified when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5, indicating a minor version bump in the page’s revision history. This appears to be maintenance-oriented and does not change the study content or outcomes.
    Difference
    0.0%
    Check dated 2026-08-11T14:36:19.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.3 to v3.6.4, indicating a deployment/upgrade of the Study Details page.
    Difference
    0.0%
    Check dated 2026-07-28T05:46:02.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.6.2 to v3.6.3, signaling a newer version of the study record. This reflects a metadata update rather than a modification to study details or content visible to users.
    Difference
    0.0%
    Check dated 2026-07-06T16:22:19.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.0 to v3.6.2, indicating a newer build of the study page.
    Difference
    0.0%
    Check dated 2026-06-29T11:00:01.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    Enrollment status is updated to 'No longer looking for participants', clarifying that recruitment has ended. The page also adds or reorganizes helpful sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment header to reflect current content structure.
    Difference
    0.4%
    Check dated 2026-06-15T08:31:22.000Z thumbnail image
  9. Check
    82 days ago
    Change Detected
    Summary
    The study plan section was updated to replace and augment several safety and efficacy endpoints with standardized definitions (e.g., DLT rate by CTCAE v5.0, ORR by RECIST v1.1, and PFS/OS) and to include a comprehensive set of pharmacokinetic endpoints. Older endpoint definitions (per-dose-level DLT rate, peak PK measures, and certain PK analyses) were removed and clarified to align with current terminology.
    Difference
    1%
    Check dated 2026-06-08T04:26:39.000Z thumbnail image

Stay in the know with updates to Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.